Agios Pharmaceuticals, Inc. filings document the regulatory record of a Delaware, Nasdaq-listed commercial-stage biopharmaceutical company focused on rare diseases and hematology. Its 8-K reports furnish operating results, product revenue updates for PYRUKYND® and AQVESME™, business highlights, investor presentations, and Regulation FD disclosures tied to mitapivat commercialization, clinical programs, and regulatory interactions.
Proxy and current-report filings cover annual-meeting proposals, director elections, board-class structure, committee assignments, stockholder voting matters, and compensatory arrangements for directors. Other disclosures address board appointments, pharmacovigilance communications involving PYRUKYND, exhibit filings, and Inline XBRL cover-page data.
AGIOS PHARMACEUTICALS director Catherine Owen Adams exercised restricted stock units into common stock. She converted 1,976 restricted stock units into 1,976 shares of common stock at a stated price of $0.00 per share and did not sell any shares. Following the transaction, she directly holds 8,049 shares of common stock. The restricted stock units were granted on June 13, 2023 and vest in three equal annual installments beginning on June 13, 2024, with vested shares delivered within three business days after vesting.
AGIOS PHARMACEUTICALS, INC. director Jeffrey D. Capello reported the vesting and conversion of previously granted restricted stock units into common shares. On June 13, 2026, he exercised 1,976 restricted stock units into 1,976 shares of common stock at a stated price of $0.00 per share, reflecting a compensation-related equity award rather than an open-market purchase. These units were part of a grant made on June 13, 2023, scheduled to vest in three equal annual installments beginning June 13, 2024. After this transaction, Capello directly holds 8,049 shares of Agios common stock.
Agios Pharmaceuticals ownership filing shows Armistice Capital, LLC and Steven Boyd report beneficial ownership of 2,716,000 shares of common stock, representing 4.57% of the class. The filing states Armistice Capital exercises shared voting and dispositive power over those shares under an Investment Management Agreement.
The filing explains the Master Fund is the direct holder and that Mr. Boyd, as managing member of Armistice Capital, may be deemed to beneficially own the securities held by the Master Fund. Signatures are dated May 15, 2026.
Agios Pharmaceuticals ownership update: Lynx1 Capital Management and Weston Nichols report beneficial ownership of 3,013,949 shares of Agios common stock, representing 5.1% of the class. The percentage is calculated using 59,471,609 shares outstanding as of April 24, 2026.
The filing states the shares are held by Lynx1 Master Fund LP with shared voting and dispositive power, and the statement is a joint filing by the Investment Manager and Mr. Nichols.
Agios Pharmaceuticals Inc: Vanguard Capital Management reports beneficial ownership of 3,088,169 shares of Agios common stock, representing 5.27% of the class as of 03/31/2026. Vanguard reports sole dispositive power over the 3,088,169 shares and sole voting power over 455,853 shares. The filing states these holdings reflect positions managed by Vanguard Capital Management LLC and specified affiliates, including shares held by Vanguard funds and managed accounts.
Agios Pharmaceuticals reported first-quarter 2026 product revenue of $20.7 million, up from $8.7 million a year earlier, driven by PYRUKYND® and the late-2025 U.S. launch of AQVESME™ for thalassemia and initial rest-of-world sales.
The company posted a net loss of $99.1 million, or $1.69 per share, as it increased research and development spending to $81.1 million and selling, general and administrative costs to $48.3 million to support its expanding rare-disease portfolio and commercialization.
Agios ended March 31, 2026 with $1.0 billion in cash, cash equivalents and marketable securities, and expects this to fund operations for at least 12 months while advancing mitapivat in thalassemia and sickle cell disease, tebapivat in lower-risk MDS and SCD, AG-181 in PKU, and AG-236 in polycythemia vera.
Agios Pharmaceuticals reported first quarter 2026 results showing rapid growth in its rare disease franchise but continued investment-driven losses. Mitapivat (PYRUKYND® and AQVESME™) generated worldwide net revenues of $20.7 million, up from $8.7 million in the first quarter of 2025, supported by a strong U.S. launch of AQVESME in thalassemia with 242 prescriptions written as of March 31, 2026.
Net loss for the quarter was $99.1 million compared to $89.3 million a year earlier, reflecting higher R&D spending of $81.1 million and SG&A expenses of $48.3 million. Cash, cash equivalents and marketable securities totaled $1.0 billion as of March 31, 2026. The company plans to submit a supplemental NDA for mitapivat in sickle cell disease in the second quarter of 2026 and expects Phase 2 tebapivat readouts in myelodysplastic syndromes and sickle cell disease later in 2026.
Agios Pharmaceuticals is holding its 2026 Annual Meeting of Stockholders as a fully virtual webcast on June 18, 2026 at 9:00 a.m. Eastern Time. Stockholders of record at the close of business on April 21, 2026, when 59,471,609 common shares were outstanding, may vote.
Items up for vote include electing three Class I directors to terms ending in 2029, an advisory say‑on‑pay vote on executive compensation, approval of an amendment to the 2023 Stock Incentive Plan to increase available shares, and ratification of PricewaterhouseCoopers LLP as independent auditor for 2026. A majority of outstanding shares, about 29,735,805, is needed for a quorum. The company uses internet “notice and access” and emphasizes ESG initiatives, flexible work culture and extensive governance structures.
Agios Pharmaceuticals Chief Legal Officer James William Burns exercised 8,500 performance share units into 8,500 shares of common stock. The PSUs vested when a specified regulatory milestone was determined to be met on April 2, 2026. On the same date, 3,280 shares were sold at $34.71 per share to cover tax withholding obligations under durable automatic sale instructions consistent with Rule 10b5-1(c). Following these transactions, Burns directly holds 49,306 shares of Agios common stock.